Skip to main content
Clinical Trials/NCT02270333
NCT02270333
Completed
Not Applicable

Effects of Inspiratory Muscle Training in Patients With Sarcoidosis

Gazi University0 sites30 target enrollmentApril 2012
ConditionsSarcoidosis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sarcoidosis
Sponsor
Gazi University
Enrollment
30
Primary Endpoint
Maximum inspiratory and expiratory muscle strength (MIP, MEP)
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Respiratory muscle weakness results with decreased exercise capacity, worse fatigue, dyspnea and quality of life in patients with sarcoidosis. However, no study investigated the effects of inspiratory muscle training (IMT), therefore effects of IMT on outcomes in patients with sarcoidosis were investigated.

Detailed Description

Patients were diagnosed with sarcoidosis according to the criteria of the latest American Thoracic Society (ATS)/European Respiratory Society (ERS)/World Association of Sarcoidosis and Other Granulomatous (WASOG) Disorders statement on sarcoidosis. Primary outcome measurement was respiratory muscle strength, secondary outcomes were, exercise capacity quality of life, fatigue and depression.

Registry
clinicaltrials.gov
Start Date
April 2012
End Date
April 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Meral Boşnak Güçlü

Assoc. Prof.

Gazi University

Eligibility Criteria

Inclusion Criteria

  • Clinically stable
  • Under standard medication
  • Stage I and IV
  • No change in medications over three months

Exclusion Criteria

  • Cognitive disorders
  • Current corticosteroid use
  • Having co-morbidity to prevent performing IMT
  • Acute infection
  • Orthopedic and neurological problems

Outcomes

Primary Outcomes

Maximum inspiratory and expiratory muscle strength (MIP, MEP)

Time Frame: 6 weeks

Mouth pressure device

Secondary Outcomes

  • Exercise Capacity(6 weeks)
  • Pulmonary function and diffusing capacity(6 weeks)
  • Fatigue(6 weeks)
  • Dyspnea(6 weeks)
  • Maximal Exercise Capacity(6 weeks)
  • Peripheral muscle strength(6 weeks)
  • Quality of life(6 weeks)
  • Depression(6 weeks)

Similar Trials